SUPAC-MR final guidance increases allowable Level 1 content variation from 2% to 5%.
• By The Pink Sheet
SUPAC-MR FINAL GUIDANCE INCREASES LEVEL 1 CONTENT VARIATION FROM 2% TO 5% for release-controlling excipients for all extended- and delayed-release solid oral dosage forms. The Scale-Up and Post-Approval Changes guidance for Modified-Release Solid Oral Dosage Forms, finalized on Oct. 6, states that for Level 1 components and composition changes, "the total additive effect of all release-controlling excipient changes should not be more than 5% [by weight] of the total release-controlling excipients in the original approved formulation." Such changes would be filed in an annual report. The draft SUPAC-MR guidance, released in August 1996, only allowed for Level 1 release-controlling excipient changes up to 2% of the total weight ("The Pink Sheet" Aug. 5, 1996, T&G-12).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.